US-Mexico-Canada Agreement exclusivity period raises concerns

Oct 3, 2018

US-Mexico-Canada Agreement includes 10 year exclusivity period for biologic drugs, raising concerns that competition will be hindered to the disadvantage of consumers and health services in those regions. Currently the exclusivity period stands at 8 years in Canada and 5 years in Mexico.

Print Page Mail Article